View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 30, 2021updated 12 Jul 2022 11:06am

Indian pharma companies partner to trial molnupiravir for Covid-19

The companies will collectively sponsor, manage and track the trial, which will be performed by Dr Reddy’s using its product.

Five Indian pharmaceutical companies have partnered to conduct a clinical trial of Merck (MSD)’s experimental antiviral candidate molnupiravir to treat mild Covid-19 in an outpatient setting.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The partners are Cipla, Dr Reddy’s Laboratories, Sun Pharmaceutical Industries and Torrent Pharmaceuticals.

These companies separately signed non-exclusive voluntary licensing agreements with Merck between March and April this year to manufacture and supply the drug to India and more than 100 low and middle-income countries.

Molnupiravir is an oral drug designed to block the replication of various RNA viruses, including the SARS-CoV-2 virus.

Under the latest agreement, the partners will together sponsor, oversee and track the trial of the drug candidate in India.

Dr Reddy’s will perform the trial using its product, according to a directive issued by the Central Drugs Standard Control Organization’s Subject Expert Committee.

The remaining four companies must establish the equivalence of their product to Dr Reddy’s product.

Set to be carried out between this month and September 2021, the trial will follow the protocol approved by the Drugs Controller General of India. It will enrol 1,200 patients with mild Covid-19 across India.

If the study yields positive data, each of the five companies will individually seek regulatory approvals to produce and distribute molnupiravir for Covid-19 in the country.

Merck and its partner Ridgeback Biotherapeutics are currently assessing the drug in a global Phase III trial to treat non-hospitalised Covid-19 patients.

Earlier this year, Merck and Ridgeback reported preliminary data from a Phase IIa Covid-19 trial of molnupiravir in the US.

Data showed a decrease in time to negativity of infectious virus isolation in nasopharyngeal swabs from patients with symptomatic Covid-19.

In another development, Cipla has obtained regulatory approval to distribute Moderna’s Covid-19 vaccine in India, reported Reuters citing a senior government official.

While a definitive deal for commercial supply is yet to be signed, Cipla is aiding Moderna in the regulatory approval and the import of vaccines to be donated to the country.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena